Rationale for the ASSAIL-MI-trial: a randomised controlled trial designed to assess the effect of tocilizumab on myocardial salvage in patients with acute ST-elevation myocardial infarction (STEMI)

INTRODUCTION: Interleukin-6 (IL-6) may be involved in ischaemia-reperfusion injury and myocardial remodelling after myocardial infarction (MI). We have recently shown that IL-6 inhibition by tocilizumab attenuates systemic inflammation and troponin T-release in patients with acute non-ST elevation M...

Descripción completa

Detalles Bibliográficos
Autores principales: Anstensrud, Anne Kristine, Woxholt, Sindre, Sharma, Kapil, Broch, Kaspar, Bendz, Bjørn, Aakhus, Svend, Ueland, Thor, Amundsen, Brage H, Damås, Jan Kristian, Hopp, Einar, Kleveland, Ola, Stensæth, Knut Haakon, Opdahl, Anders, Kløw, Nils-Einar, Seljeflot, Ingebjørg, Andersen, Geir Øystein, Wiseth, Rune, Aukrust, Pål, Gullestad, Lars
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6803013/
https://www.ncbi.nlm.nih.gov/pubmed/31673391
http://dx.doi.org/10.1136/openhrt-2019-001108

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6803013/
https://www.ncbi.nlm.nih.gov/pubmed/31673391
http://dx.doi.org/10.1136/openhrt-2019-001108

Ejemplares similares